Cargando…

Infliximab in the treatment of tislelizumab-induced steroid-refractory immune checkpoint inhibitor-related pneumonia: case report and literature review

BACKGROUND: Infliximab has been recommended by the American Society of Clinical Oncology (ASCO) guidelines for the treatment of steroid-refractory immune checkpoint inhibitor-related pneumonia (CIP), but clinical evidence remains insufficient. In order to improve the level of diagnosis and treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Zhujun, He, Jian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9552064/ https://www.ncbi.nlm.nih.gov/pubmed/36237233 http://dx.doi.org/10.21037/tcr-22-1162

Ejemplares similares

Infliximab for Steroid-Refractory Immune Checkpoint Inhibitor-Induced Acute Pancreatitis
por: Townsend, Matthew J., et al.
Publicado: (2023)

Infliximab for the treatment of refractory immune-related hepatitis secondary to checkpoint inhibitors: A case report
por: Corrigan, Margaret, et al.
Publicado: (2019)

The Current status of steroid-refractory immune-checkpoint-inhibitor-related hepatotoxicity
por: Xing, Hui, et al.
Publicado: (2023)

Steroid-Refractory Immune-Related Adverse Events Induced by Checkpoint Inhibitors
por: Tomsitz, Dirk, et al.
Publicado: (2023)

Treatment of corticosteroid refractory immune checkpoint inhibitor myocarditis with Infliximab: a case series
por: Zhang, Robert S., et al.
Publicado: (2021)

Refractory constrictive pericarditis caused by an immune checkpoint inhibitor properly managed with infliximab: a case report
por: Moriyama, Shohei, et al.
Publicado: (2021)

Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab
por: Alexander, James L, et al.
Publicado: (2021)

Vedolizumab Attenuates Immune-Checkpoint-Therapy-Induced Infliximab-Refractory Colitis
por: Kaneoka, Ayaka, et al.
Publicado: (2022)

Real World Outcomes and Hepatotoxicity of Infliximab in the Treatment of Steroid-Refractory Immune-Related Adverse Events
por: Araujo, Daniel V., et al.
Publicado: (2021)

Pulse corticosteroid therapy in the treatment of steroid-refractory immune checkpoint inhibitor-related pneumonitis: Case report and review
por: Lai, Kuan-Chang, et al.
Publicado: (2022)

Calcineurin inhibitors in steroid and anti‐TNF‐alpha refractory immune checkpoint inhibitor colitis
por: Zhang, Eva, et al.
Publicado: (2021)

A case report of steroid-refractory bullous pemphigoid induced by immune checkpoint inhibitor therapy
por: Guan, Shasha, et al.
Publicado: (2023)

Case Report: Successful Treatment of Steroid-Refractory Immune Checkpoint Inhibitor-Related Pure Red Cell Aplasia With Cyclosporin
por: Gérard, Alexandre, et al.
Publicado: (2020)

Management of pembrolizumab-induced steroid refractory mucositis with infliximab: A case report
por: Dang, Harry, et al.
Publicado: (2020)

The efficacy and safety of infliximab and calcineurin inhibitors in steroid-refractory UC patients: A meta-analysis
por: Zhao, Heng-Nan, et al.
Publicado: (2021)

Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab
por: Zhang, Hao Chi, et al.
Publicado: (2019)

Ipilimumab and Nivolumab induced steroid-refractory colitis treated with infliximab: A case report
por: Nassri, Ammar B, et al.
Publicado: (2019)

A Case of Immune Checkpoint Inhibitor Refractory Colitis Treated with Mycophenolate and High-dose Steroids
por: Alcantar, Daniel, et al.
Publicado: (2019)

Real-world insights on preferred treatments for steroid-refractory immune checkpoint inhibitor-induced pneumonitis
por: Gatti-Mays, Margaret, et al.
Publicado: (2021)

Tislelizumab-related enteritis successfully treated with adalimumab: A case report
por: Chen, Na, et al.
Publicado: (2022)

Risk factors and immunomodulators use in steroid-refractory checkpoint inhibitor pneumonitis
por: Li, Yanlin, et al.
Publicado: (2023)

Nintedanib in an elderly non-small-cell lung cancer patient with severe steroid-refractory checkpoint inhibitor-related pneumonitis: A case report and literature review
por: Pan, Lei, et al.
Publicado: (2023)

Case Report: Successful Management of a Refractory Plasmablastic Lymphoma Patient With Tislelizumab and Lenalidomide
por: Cheng, Lili, et al.
Publicado: (2021)

Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade
por: Beattie, Jason, et al.
Publicado: (2021)

A case report of immune checkpoint inhibitor-related steroid-refractory myocarditis and myasthenia gravis-like myositis treated with abatacept and mycophenolate mofetil
por: Jespersen, Mette Syberg, et al.
Publicado: (2021)

Severe thyrotoxicosis induced by tislelizumab: a case report and literature review
por: Huo, Liman, et al.
Publicado: (2023)

Vedolizumab in combined immune checkpoint therapy-induced infliximab-refractory colitis in a patient with metastatic melanoma: A case report
por: Randhawa, Manreet, et al.
Publicado: (2019)

Letter to the editor regarding “The efficacy and safety of infliximab and calcineurin inhibitors in steroid-refractory UC patients: A meta-analysis”
por: Zhu, Qingcheng, et al.
Publicado: (2022)

Treatment of mycophenolate-resistant immune-related organizing pneumonia with infliximab
por: Ortega Sanchez, Guacimara, et al.
Publicado: (2018)

Risk Factors for Refractory Immune Checkpoint Inhibitor-related Pneumonitis in Patients With Lung Cancer
por: Tan, Peixin, et al.
Publicado: (2023)

A case report and literature review of immune checkpoint inhibitor-associated pneumonia caused by penpulimab
por: Gao, Rongmao, et al.
Publicado: (2023)

Taking the bull by the horn: the frontline use of infliximab for the treatment of immune checkpoint inhibitor-induced enterocolitis
por: Esfahani, Khashayar
Publicado: (2018)

Biologic Therapy for Refractory Immune Checkpoint Inhibitor Colitis
por: Alorfi, Nasser M, et al.
Publicado: (2022)

Rapid Improvement Following Receipt of Infliximab in Steroid-refractory Durvalumab-Associated Grade 3 Pneumonitis
por: Huang, Sherri, et al.
Publicado: (2022)

Case Report: Treatment for steroid-refractory immune-related myocarditis with tofacitinib
por: Xing, Qian, et al.
Publicado: (2022)

Rituximab in steroid-refractory immune-related pancreatitis: a case report
por: Santoro, Armando, et al.
Publicado: (2023)

Infliximab for the treatment of refractory scleritis
por: Doctor, Priyanka, et al.
Publicado: (2009)

Efficacy and safety of Infliximab for steroid-resistant immune-related adverse events: A retrospective study
por: Kadokawa, Yukio, et al.
Publicado: (2021)

Inflammatory Cytokine Inhibition with Combination Daclizumab and Infliximab for Steroid Refractory Acute Graft-Versus-Host Disease
por: Rager, Alison, et al.
Publicado: (2010)

Rheumatoid Arthritis: Refractory to Infliximab, a Tumor Necrosis Factor Inhibitor
por: Solehan, Hana Maizuliana bt, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_16fsp7ip2bn440fp37jd8d66gk